In IVF-ET cycles—

Comparable Pregnancy Rates With Fewer Doses Versus Capsules Administered Vaginally¹

Study design: Results of a prospective, randomized study of 244 women receiving progesterone for IVF-ET or ICSI cycles. Patients received Crinone (90 mg QD) or Utrogestan® progesterone capsules used vaginally (200 mg TID). In both groups, progesterone support began the day after oocyte retrieval and continued until the day the pregnancy test was performed or until week 12 in the case of pregnancy.

Utrogestan is manufactured by Laboratory Besins International. This product is marketed in the United States by Solvay Pharmaceuticals, Inc., as Prometrium^®. Prometrium is a registered trademark of Solvay Pharmaceuticals, Inc.

Reference: 1. Geber S, Moreira AC, de Paula SO, Sampaio M. Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. Reprod BioMed Online. 2007;14:155–158. Available at: rbmonline.com/Article/2551.